CDXC Logo

ChromaDex Corporation (CDXC) 

NASDAQ
Market Cap
$582.89M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
313 of 774
Rank in Industry
184 of 432

Largest Insider Buys in Sector

CDXC Stock Price History Chart

CDXC Stock Performance

About ChromaDex Corporation

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of …

Insider Activity of ChromaDex Corporation

Over the last 12 months, insiders at ChromaDex Corporation have bought $7,050 and sold $82,110 worth of ChromaDex Corporation stock.

On average, over the past 5 years, insiders at ChromaDex Corporation have bought $73,149.23B and sold $182,873.08B worth of stock each year.

Highest buying activity among insiders over the last 12 months: Chau Hoi Shuen Solina Holly (10 percent owner) — $365,746.17B. Gerber Brianna (Chief Financial Officer) — $7,050.

The last purchase of 11,408,715 shares for transaction amount of $365,746.17B was made by Chau Hoi Shuen Solina Holly (10 percent owner) on 2024‑08‑20.

List of Insider Buy and Sell Transactions, ChromaDex Corporation

2024-08-23Saledirector
23,000
0.0308%
$3.57$82,110-0.28%
2024-08-20Sale10 percent owner
11.41M
$32.06M$365,746.17B+4.64%
2024-08-20Purchase10 percent owner
11.41M
$32.06M$365,746.17B+4.64%
2023-12-01PurchaseChief Financial Officer
5,000
0.0067%
$1.41$7,050+117.73%
2023-09-06Purchase
3.47M
2.9817%
$1.00$3.47M+4.52%
2023-06-12Purchasedirector
7,000
0.0089%
$1.69$11,830-11.30%
2023-05-31PurchaseChief Executive Officer
7,000
0.0094%
$1.42$9,940+10.64%
2023-05-25Purchasedirector
7,000
0.0096%
$1.46$10,220+8.39%
2022-09-30Purchase
960,000
1.3206%
$1.25$1.2M+29.27%
2022-09-30PurchaseCheif Executive Officer
80,000
0.11%
$1.25$100,000+29.27%
2022-06-16Purchase
60,037
0.0891%
$1.66$99,878-1.22%
2022-03-16PurchaseCEO
25,000
0.0364%
$2.16$54,000-19.35%
2021-05-13PurchaseCEO
10,000
0.0147%
$6.65$66,500-9.16%
2021-03-16Saledirector
20,000
0.0316%
$13.17$263,400-48.04%
2021-03-15Saledirector
32,500
0.0477%
$11.15$362,375-42.77%
2020-12-10SaleEXECUTIVE CHAIRMAN OF BOARD
37,829
0.0609%
$5.19$196,333+50.38%
2020-11-06PurchaseCHIEF FINANCIAL OFFICER
5,000
0.008%
$4.43$22,150+75.28%
2020-05-19PurchaseCEO
1,000
0.0017%
$4.69$4,690+9.12%
2019-11-14PurchaseCEO
10,000
0.0176%
$3.09$30,900+44.97%
2019-08-23PurchaseCEO
2,500
0.0045%
$4.03$10,075+6.62%

Insider Historical Profitability

7.76%
Gerber BriannaChief Financial Officer
27436
0.0359%
$7.6310
FROST PHILLIP MD ET AL10 percent owner
15252937
19.9689%
$7.6381<0.0001%
Champion River Ventures Ltd
11408715
14.9361%
$7.6340+10.25%
Dvorak International Ltd
7885641
10.3238%
$7.6320+14.02%
Brauser Michaeldirector
4519926
5.9174%
$7.6380+4.87%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$10.61M4.043.05M0%+$0<0.0001
Tieton Capital Management LLC$10.52M43.02M+3.71%+$376,531.525.52
ICONIQ Capital$4.51M1.721.3M0%+$00.08
BlackRock$3.14M1.2902,953-0.19%-$6,051.72<0.0001
Millennium Management LLC$2.03M0.77584,282+367.07%+$1.6M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.